Drug Profile
Research programme: retinitis pigmentosa gene therapies - Astellas Pharma/Harvard Medical School
Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Harvard Medical School
- Developer Astellas Pharma; Harvard Medical School
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinitis pigmentosa
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for research development in Retinitis-pigmentosa in Japan (Parenteral, Injection)
- 28 Nov 2018 No recent reports of development identified for research development in Retinitis-pigmentosa in USA (Parenteral, Injection)
- 14 Oct 2014 Early research in Retinitis pigmentosa in Japan (Parenteral)